T2 Biosystems Named 2013 SBANE New England Innovation Award Winner

T2 Biosystems Named 2013 SBANE New England Innovation Award Winner

May 9, 2013


T2 Biosystems, a company developing direct detection products enabling superior diagnostics, has been awarded the 2013 Rising Star Award by the Smaller Business Association of New England (SBANE). The SBANE New England Innovation Award recipients are chosen from a field of over 200 nominees and represent companies headquartered in New England that are judged to be leaders in their field with technologies, products and services that will have a compelling benefit to their users and a significant commercial impact.

“T2 Biosystems is honored to receive the 2013 Rising Star award and we thank the Smaller Business Association of New England for this recognition,” said John McDonough, President and CEO of T2 Biosystems. “This award is particularly meaningful to T2 Bio as SBANE seeks to acknowledge innovative companies in New England. We feel that the T2MR technology has the potential to fundamentally improve healthcare for patients and physicians alike with a new generation of rapid and accurate diagnostics, exemplified by our flagship T2Candida®test.”

Innovation is at the heart of economic prosperity and SBANE continues to recognize those companies and organizations that have transformed their innovative ideas into a product or service that delivers proven value to customers. Former winners come from varying fields such as technology, manufacturing, service (both for profit and not for profit) and retail / distribution. Winners include notable companies such as Staples, PictureTel, Ben & Jerry’s, Brooks Automation, Direct Tire, Genzyme, Nantucket Nectars, Imagitas!, Aurora Imaging Technology and iRobot.

About T2 Biosystems

T2 Biosystems is disrupting the landscape of clinical diagnostics with T2MR®, the Company’s proprietary magnetic biosensor detector. The T2MR technology enables healthcare professionals to save lives and reduce costs by providing sensitive, accurate and rapid assay results. The Company’s products detect molecular, hemostasis or immunodiagnostic targets directly from unpurified clinical samples in hospitals, labs and physicians’ offices. For more information, please visit www.t2biosystems.com.


MacDougall Biomedical Communications
Chris Erdman, 781-235-3060